Xu M - Search Results

1

Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation.

Wu W, Liu Y, Jin Y, Liu L, Guo Y, Xu M, Hao Q, Li D, Fang W, Zhang A, Zhao P. Wu W, et al. Among authors: xu m. Front Med (Lausanne). 2022 Jan 13;8:746637. doi: 10.3389/fmed.2021.746637. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35096857 Free PMC article.

2

Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report.

Li W, Ma Z, Fu X, Hao Z, Shang H, Shi J, Lei M, Xu M, Ning S, Hua X. Li W, et al. Among authors: xu m. Ann Transl Med. 2021 Sep;9(18):1487. doi: 10.21037/atm-21-3681. Ann Transl Med. 2021. PMID: 34734039 Free PMC article.

3

A novel fusion between CDC42BPB and ALK in a patient with quadruple wild-type gastrointestinal stromal tumor.

Huang W, Yuan W, Ren L, Xu C, Luo R, Zhou Y, Lu W, Hao Q, Xu M, Hou Y. Huang W, et al. Among authors: xu m, xu c. Mol Genet Genomic Med. 2022 May;10(5):e1881. doi: 10.1002/mgg3.1881. Epub 2022 Mar 23. Mol Genet Genomic Med. 2022. PMID: 35319816 Free PMC article.

4

Response to crizotinib in a patient with MET-amplified hepatocellular carcinoma.

Chen Q, Xie C, Feng K, Huang H, Xiong C, Lin T, Wang W, Xu M, Yang X, Zhong C. Chen Q, et al. Among authors: xu m. Hepatol Res. 2021 Nov;51(11):1164-1169. doi: 10.1111/hepr.13664. Epub 2021 Jun 8. Hepatol Res. 2021. PMID: 33991153

5

Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy.

Li Y, Liu Y, Qu Y, Chen X, Qu X, Ye Y, Du X, Cheng Y, Xu M, Zhang H. Li Y, et al. Among authors: xu m. Front Immunol. 2022 May 6;13:832593. doi: 10.3389/fimmu.2022.832593. eCollection 2022. Front Immunol. 2022. PMID: 35603147 Free PMC article.

6

Colorectal leiomyosarcoma with BRCA2 mutation benefit from treatment with olaparib: a case report.

Hong L, Wang YN, Zhang X, Zhou X, Fan S, Xu M, Zhang S, Jiang D. Hong L, et al. Among authors: xu m. J Gastrointest Oncol. 2022 Jun;13(3):1499-1504. doi: 10.21037/jgo-22-419. J Gastrointest Oncol. 2022. PMID: 35837171 Free PMC article.

7

Differences in DNA damage repair gene mutations between left- and right-sided colorectal cancer.

Huang W, Li W, Xu N, Li H, Zhang Z, Zhang X, He T, Yao J, Xu M, He Q, Guo L, Zhang S. Huang W, et al. Among authors: xu m, xu n. Cancer Med. 2023 May;12(9):10187-10198. doi: 10.1002/cam4.5716. Epub 2023 Apr 25. Cancer Med. 2023. PMID: 37096801 Free PMC article.

8

Next generation sequencing predicting clinical effect of immunotherapy on adult rhabdomyosarcoma patient: A case report.

Sun X, Wang X, Zhou J, Xu Y, Zhang H, Xu M, Shen J, Shi X, Song W, Li J. Sun X, et al. Among authors: xu m, xu y. Medicine (Baltimore). 2023 May 26;102(21):e33858. doi: 10.1097/MD.0000000000033858. Medicine (Baltimore). 2023. PMID: 37233406 Free PMC article.

9

Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.

Lu Y, Li Z, Zhu H, Zhao J, Xu M, Gu W. Lu Y, et al. Among authors: xu m. Ann Palliat Med. 2021 Dec;10(12):12886-12893. doi: 10.21037/apm-21-2016. Ann Palliat Med. 2021. PMID: 35016432 Free article.

10

Appearance of an ALK mutation conferring resistance to crizotinib in non-small cell lung cancer harboring oncogenic ROS1 fusion.

Li Z, Lin Y, Chi X, Xu M, Wang H. Li Z, et al. Among authors: xu m. Lung Cancer. 2021 Mar;153:174-175. doi: 10.1016/j.lungcan.2021.01.001. Epub 2021 Jan 8. Lung Cancer. 2021. PMID: 33472762 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22,512 results

Search Page

Filters